Sabre Adopts "Poison Pill" Defense
Travel tech firm Sabre Corporation has adopted a limited-duration shareholder rights plan, a classic "poison pill" defense. The move is a direct response to a substantial accumulation of its stock by Constellation Software. This strategy is designed to prevent a hostile takeover by making it prohibitively expensive for any single entity to acquire a controlling stake.
The shareholder rights plan is set to expire in one year and would be triggered if any person or group acquires 15% or more of Sabre's outstanding common stock, or 20% for passive investors. If triggered, the plan allows existing shareholders, other than the acquirer, to purchase additional shares at a 50% discount. This defensive measure is a direct response to Constellation Software's accumulation of a 9.7% stake in Sabre between April and November 2025. Constellation's stake is comprised of 4.7% in common stock and another 5% through derivative instruments. The software company first disclosed its position to Sabre in January 2026, and subsequently requested two seats on Sabre's board of directors. Despite nearing a strategic agreement, Constellation abruptly ended negotiations on February 26, 2026, prompting Sabre's defensive move. Constellation Software is known for its aggressive acquisition strategy, having acquired over 500 businesses by April 2024. The company's typical model involves buying and holding smaller, profitable software firms in niche vertical markets, then allowing them to operate with a high degree of autonomy. One of its operating groups, Vela Software, has been particularly active in acquiring travel technology companies. This defensive maneuver comes as Sabre has been working on a financial turnaround. For the full year 2025, the company reported a modest 1% revenue increase to $2.8 billion and paid down over $1 billion in debt. The company also turned a significant net income of $525 million for 2025, a substantial improvement from a net loss of $279 million in 2024. Sabre's stock has seen a significant decline over the past year, down over 74%. However, in the trading sessions leading up to the announcement, the stock had seen a double-digit percentage increase. The company's 52-week high is $4.22 per share, with its recent price hovering just above its 52-week low of $0.81.
